EndoBind detects endogenous protein-protein interactions in real time.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 26 01 2021
accepted: 24 08 2021
entrez: 16 9 2021
pubmed: 17 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

We present two high-throughput compatible methods to detect the interaction of ectopically expressed (RT-Bind) or endogenously tagged (EndoBind) proteins of interest. Both approaches provide temporal evaluation of dimer formation over an extended duration. Using examples of the Nrf2-KEAP1 and the CRAF-KRAS-G12V interaction, we demonstrate that our method allows for the detection of signal for more than 2 days after substrate addition, allowing for continuous monitoring of endogenous protein-protein interactions in real time.

Identifiants

pubmed: 34526658
doi: 10.1038/s42003-021-02600-5
pii: 10.1038/s42003-021-02600-5
pmc: PMC8443649
doi:

Substances chimiques

KEAP1 protein, human 0
KRAS protein, human 0
Kelch-Like ECH-Associated Protein 1 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1085

Informations de copyright

© 2021. The Author(s).

Références

Chem Res Toxicol. 2005 Dec;18(12):1917-26
pubmed: 16359182
J Biol Chem. 2016 Nov 18;291(47):24579-24593
pubmed: 27703006
J Med Chem. 2016 Apr 28;59(8):3991-4006
pubmed: 27031670
Chem Biol. 2006 Feb;13(2):213-23
pubmed: 16492569
Free Radic Biol Med. 2015 Nov;88(Pt B):101-107
pubmed: 26057936
Cancer Cell. 2016 Sep 12;30(3):485-498
pubmed: 27523909
ChemMedChem. 2016 Apr 19;11(8):738-56
pubmed: 26864455
J Allergy Clin Immunol. 2019 Jul;144(1):224-235
pubmed: 30707971
Nat Rev Drug Discov. 2020 Aug;19(8):533-552
pubmed: 32528145
Nat Rev Cancer. 2017 Nov;17(11):676-691
pubmed: 28984291
J Biol Chem. 2013 Jan 25;288(4):2403-13
pubmed: 23188824
Biochem Pharmacol. 2018 Feb;148:298-307
pubmed: 29309765
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14746-53
pubmed: 22908297
Nat Med. 2005 Sep;11(9):920-2
pubmed: 16145569
ACS Chem Biol. 2016 Feb 19;11(2):400-8
pubmed: 26569370
FASEB J. 2019 Mar;33(3):3841-3850
pubmed: 30521377
Clin Cancer Res. 2007 Mar 1;13(5):1576-83
pubmed: 17332304
Breast Cancer Res. 2008;10(2):R33
pubmed: 18430202
Anal Biochem. 2017 Apr 1;522:10-17
pubmed: 28115169
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):57-62
pubmed: 16371460

Auteurs

Anke Bill (A)

Novartis Institute for Biochemical Research, Oncology, Cambridge, MA, USA. anke.bill@novartis.com.

Sheryll Espinola (S)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Daniel Guthy (D)

Novartis Institute for Biochemical Research, Oncology, Basel, Switzerland.

Jacob R Haling (JR)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.
Mirati Therapeutics, Inc., Research, San Diego, CA, USA.

Mylene Lanter (M)

Novartis Institute for Biochemical Research, Oncology, Basel, Switzerland.

Min Lu (M)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Anthony Marelli (A)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Angelica Mendiola (A)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Loren Miraglia (L)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Brandon L Taylor (BL)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Leonardo Vargas (L)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Anthony P Orth (AP)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.

Frederick J King (FJ)

Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. fred.king@novartis.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH